All In Biotech

Drug Trial Radar · NCT06897930

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Apr 21, 2025

Primary completion

May 1, 2029

Study completion May 1, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • AZD0120Biological

    Single infusion of AZD0120 on visit DAY 1 after completing required lymphodepleting chemotherapy..

  • CyclophosphamideDrug

    Lymphodepletion - specified dose prior to receiving AZD0120

  • FludarabineDrug

    Lymphodepletion - specified dose prior to receiving AZD0120

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PHASE 1B: To evaluate the safety and tolerability of AZD0120 in participants with refractory systemic lupus erythematosus (SLE)Time frame: 2 years
  2. PHASE 1B: Recommended Phase 2 Dose (RP2D) of AZD0120 in for Phase 2Time frame: 2 years
  3. PHASE 2: To evaluate the efficacy of AZD0120 in participants with refractory SLETime frame: 2 years

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    Stanford, California · Withdrawn

  • Research Site

    Tampa, Florida · Withdrawn

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Baltimore, Maryland · Not yet recruiting

  • Research Site

    Bethesda, Maryland · Withdrawn

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Syracuse, New York · Recruiting

  • Research Site

    Chapel Hill, North Carolina · Recruiting

  • Research Site

    Charlotte, North Carolina · Recruiting

  • Research Site

    Richmond, Virginia · Not yet recruiting

  • Research Site

    Seattle, Washington · Recruiting

  • Research Site

    Seattle, Washington · Recruiting

  • Research Site

    Darlinghurst, Australia · Recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Withdrawn

  • Research Site

    Bristol, United Kingdom · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.